Mevinolin enhances osteogenic genes (ALP, type I collagen and osteocalcin), CD44, CD47 and CD51 expression during osteogenic differentiation.
OBJECTIVE
In this study, we evaluated the effect of mevinolin on the expressions of osteogenic genes and surface molecules expression during osteogenesis.


METHODS
D1 cells were cultured in osteogenic differentiation medium (ODM) for 6 days, treated with mevinolin for 2 days, and then subjected to alizarin red S staining, MTT assays, alkaline phosphatase (ALP) activity determinations, energy dispersive X-ray spectrophotometry (EDX), real-time PCR, Western blot, fluorescence microscopy and FACS analysis.


RESULTS
Mevinolin is commonly prescribed and widely used to lower cholesterol levels, and offers an important, effective approach to the treatment of hypercholesterolemia and arteriosclerosis. However, the direct effect of mevinolin on osteogenesis in vitro has not been clarified. ODM has been previously shown to increase the osteoblast differentiation of D1 cells. In the present study, we investigated the expressions of osteogenic genes and surface molecules during osteoblast differentiation induced by mevinolin. We found that the induction of ALP, type I collagen, osteocalcin, CD44, CD47 and CD51 by mevinolin is responsible for the osteoblastic differentiation of D1 cells.


CONCLUSIONS
Our data show that mevinolin enhances the expressions of proteins and surface molecules related to osteogenesis.
Kim
Hyung Keun
HK
Department of Orthopaedics, Chonnam Natl. Univ. Hwasun Hospital, 160 Ilsimri, Hwasun-gun, Jeonnam, 519-809, Republic of Korea.
Cho
Sang Gwon
SG
Kim
Ji Hyun
JH
Doan
Thi Kim Phuong
TK
Hu
Qin Sheng
QS
Ulhaq
Rehan
R
Song
Eun Kyoo
EK
Yoon
Taek Rim
TR
D000469:Alkaline Phosphatase / Q000235:genetics / Q000378:metabolism; D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology; D051928:CD47 Antigen / Q000235:genetics / Q000378:metabolism*; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D024042:Collagen Type I / Q000235:genetics / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D018960:Hyaluronan Receptors / Q000235:genetics / Q000378:metabolism*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D039564:Integrin alphaV / Q000235:genetics / Q000378:metabolism*; D008148:Lovastatin / Q000494:pharmacology*; D051379:Mice; D039902:Multipotent Stem Cells / Q000166:cytology / Q000502:physiology; D015675:Osteocalcin / Q000235:genetics / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects / Q000235:genetics; D017154:Stromal Cells / Q000166:cytology
D051928:CD47 Antigen; D024042:Collagen Type I; D018960:Hyaluronan Receptors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D039564:Integrin alphaV; D015675:Osteocalcin; D008148:Lovastatin; D000469:Alkaline Phosphatase